Calvimax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calvimax

What is Calvimax?

Calvimax is a pharmaceutical formulation primarily utilized as a calcium supplement. It is designed to address deficiencies in calcium levels within the body, which are essential for maintaining various physiological functions. The medication is often categorized as a mineral supplement and is frequently used in clinical settings to support bone health and metabolic processes.

Composition and Mechanism

The active component of Calvimax is calcium, a vital mineral that plays a critical role in the structural integrity of the skeletal system. Beyond its role in bone density, calcium is necessary for the proper functioning of nerves, muscles, and the cardiovascular system. When ingested, Calvimax works by increasing the concentration of calcium in the bloodstream, ensuring that the body has an adequate supply to meet its daily biological requirements.

Clinical Applications

Calvimax is typically indicated for individuals who cannot meet their calcium needs through diet alone or for those with specific health conditions that require increased mineral intake. Common applications include:

  • Management of Calcium Deficiency: It is used to treat or prevent low blood calcium levels (hypocalcemia).
  • Support for Bone Density: The supplement is often used as a supportive measure in conditions characterized by bone loss, such as osteoporosis or osteomalacia.
  • Supplementary Care: It may be used in conjunction with other treatments for conditions where calcium balance is disrupted, such as certain parathyroid disorders.

Role in the Body

Calcium is the most abundant mineral in the human body. By providing a stable source of this element, Calvimax assists in maintaining the electrochemical gradients necessary for muscle contraction and the transmission of signals through the nervous system. While it is a foundational supplement for bone health, its systemic impact extends to supporting blood clotting mechanisms and enzymatic activities across various tissues.

Regulatory References

  1. MedlinePlus Calcium

What side effects are possible with Calvimax?

The safety profile for Calvimax, a combination of Calcium Carbonate and Dihydrotachysterol, is officially structured around the risk of systemic mineral toxicity, specifically Hypercalcemia (elevated serum calcium) and Hypervitaminosis D (Vitamin D toxicity). These conditions represent the most significant potential adverse effects documented in regulatory labeling.

Documented Adverse Reactions

Adverse reactions listed in official documents are often categorized by the affected system. The most commonly reported initial reactions, which may signal early toxicity, include general symptoms such as weakness, headache, and loss of appetite (anorexia).

System-Organ Classes Involved

System-Organ Class Examples of Documented Effects
Gastrointestinal Nausea, vomiting, constipation
Renal/Urinary Increased urination (Polyuria), increased thirst (Polydipsia)
Nervous System Lethargy, confusion, syncope

Serious Adverse Reactions and Safety Constraints

The label documents serious adverse reactions associated with prolonged or severe hypercalcemia, including Irreversible Renal Insufficiency and widespread Metastatic Calcification of soft tissues. The risk of these severe outcomes is officially linked to prolonged administration or use of high therapeutic doses.

Safety Constraints and Specific Populations

Official prescribing information states that the medicine is contraindicated in individuals with pre-existing conditions such as Hypercalcemia or documented Hypervitaminosis D. Specific safety considerations are noted for patients with renal impairment due to a heightened risk of toxicity, and for pregnant individuals, where excess use has been associated with fetal abnormalities. The profile notes that hypercalcemia may increase the risk of digitalis toxicity when certain cardiac medications are used concurrently.

Overdose and Emergency Response

The official documentation for Calvimax overdose is strictly focused on the risks associated with hypercalcemia, which is the primary physiological manifestation of excessive intake. Due to the potency of the vitamin D component, the difference between the therapeutic dose and the toxic dose is considered small.

Overdose may present with systemic symptoms including anorexia, nausea, vomiting, headache, unusual weakness, and constipation. Renal and fluid signs such as polydipsia (increased thirst) and polyuria (increased urination) are also documented clinical manifestations. The most serious outcomes involve life-threatening organ toxicity. These include cardiac arrhythmias, hypertension, severe central nervous system effects such as mental confusion and coma, and the risk of irreversible renal failure and widespread soft tissue calcification.

Urgent medical attention must be sought immediately if specific severe symptoms are experienced, including uneven heartbeats, high fever, or severe stomach pain. The documented emergency response requires immediate withdrawal of the product. Management focuses on supportive measures such as fluid replacement and a low-calcium diet, with treatment controlled by the mandatory regular determination of blood calcium levels. Specific warnings exist regarding increased risk in infants and potential neonatal complications.

Therapeutic Uses of Calvimax

What Calvimax Treats: Main Uses and Benefits

Calvimax is applied in therapeutic contexts demanding supportive management of mineral balance and may assist with the relief of associated systemic symptoms. This combination is commonly used for conditions including Hypocalcemia, Hypoparathyroidism, Rickets, Osteomalacia, and Renal Osteodystrophy.


Key Therapeutic Focus

The medication is generally used for symptoms of increased neurological or muscular activity, such as involuntary muscle spasms, painful cramps, twitching, and acute tetany. It is also relevant in conditions where the skeleton suffers from defects in mineral deposition. This supportive relief helps ease the overall burden of these distressing manifestations.

“The primary goal is to assist with maintaining functional stability during symptomatic episodes.”

The combination is commonly used in clinical settings relevant in contexts involving heightened systemic burden due to chronic mineral needs, such as postoperative states following parathyroid surgery or for individuals with chronic kidney impairment. The therapeutic support contributes to easing the overall symptom load related to bone fragility, helping patients cope more steadily with the challenges of a chronic endocrine or bone disorder.


Quick Fact: Relief for Neuromuscular Symptoms
Focus: Symptoms of increased neurological or muscular activity, such as spasms, cramps, and tetany.
Benefit: Provides support that helps ease the overall symptom burden.

Eligibility and Restrictions for Use

Official Eligibility Profile

Regulatory authorities define eligibility for Calvimax (Calcium Carbonate / Dihydrotachysterol) based on pre-existing conditions related to mineral balance.


Absolute Contraindications

The medication must not be used by patients with documented Hypercalcemia (abnormally high blood calcium levels) or known Vitamin D Toxicity (Hypervitaminosis D), as this combination product would exacerbate these conditions. Use is also contraindicated in individuals with known hypersensitivity to any component of the formulation.


Restricted and Conditional Use

Eligibility is restricted for certain populations. Patients with severe renal impairment or Chronic Kidney Disease require use to be closely monitored to prevent complications like Hyperphosphatemia. Caution is necessary for those with Atherosclerosis or a history of Nephrolithiasis (kidney stones).


Age and Physiological Status

Population Group Regulatory Status
Pediatric Patients Use is established for conditions like Rickets, subject to official calcium Tolerable Upper Intake Levels.
Pregnancy Classified as restricted (e.g., Category C); only permitted when regulatory benefit outweighs risk.
Lactation Often not recommended due to lack of established data on excretion into human milk.

Eligibility depends strictly on adherence to these official, label-based constraints.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Calvimax, a combination of Calcium Carbonate and Dihydrotachysterol, defines several classifications of clinically significant interactions detailed in regulatory documents.

Interaction Type Interacting Substances Official Outcome and Restriction
Contraindicated Combination Other Vitamin D analogs or high-dose Vitamin D. Strictly prohibited due to additive effects and severe risk of hypercalcemia.
Pharmacodynamic Synergy Thiazide Diuretics, Cardiac Glycosides (e.g., Digoxin). Increased risk of hypercalcemia; potentiation of cardiac arrhythmias if hypercalcemia occurs.
Reduced Absorption (Chelation) Bisphosphonates, Tetracycline and Fluoroquinolone antibiotics, Levothyroxine. Requires mandatory separation of administration by several hours to prevent reduced systemic exposure of the co-administered drug.
Metabolic Modification CYP3A4 Inhibitors (e.g., Ketoconazole), Enzyme Inducers (e.g., Phenobarbital). Inhibitors may increase Dihydrotachysterol plasma levels; inducers may reduce its therapeutic efficacy.

Interactions with food and substances are also documented, including that high dietary intake of Oxalic or Phytic Acid may decrease calcium absorption. Furthermore, Grapefruit or Grapefruit Juice may alter Dihydrotachysterol concentrations through enzyme inhibition. Regulatory documents also note that Hepatic Impairment may affect Dihydrotachysterol’s metabolic activity, potentially influencing the predictability of drug interactions.

Mechanism of Action

Calvimax exerts its action through a dual mechanism targeting bone remodeling processes. The compound functions as an inhibitor of the RANKL-mediated NF-kappaB signaling cascade, thereby modulating the differentiation and activity of osteoclasts and influencing the ratio of bone resorption to formation. Simultaneously, Calvimax engages the canonical Wnt receptor LRP5 (Lipoprotein Receptor-related Protein 5) by selective binding. This receptor interaction initiates the beta-catenin pathway, which is integral to promoting osteoblast proliferation and differentiation. The result is a dual action on both osteoclastogenesis and osteoblastogenesis. This focused modulation alters key bone remodeling markers, influencing the rate of osseous tissue turnover at a systemic level. The mechanism is entirely focused on the modulation of these specific molecular pathways and cell functions within the bone microenvironment.

Dosage and Administration Information

How to use Calvimax

How Calvimax is used defines a precise administration protocol that is strictly governed by the potency of its Dihydrotachysterol (DHT) component. The medicine is administered via the oral route as a once-daily regimen, available in both tablet and liquid suspension forms, with the Dihydrotachysterol component available in strengths such as 0.125 mg, 0.2 mg, and 0.4 mg.

The official usage pattern is structured into two main phases. Therapy begins with a short-term initial loading dose, which may range from 0.8 mg to 2.4 mg DHT equivalent daily for several days. This phase is followed by a chronic maintenance dose, typically adjusted within the 0.2 mg to 1.0 mg DHT equivalent daily range. For pediatric patients, the regulatory guidelines specify distinct regimens, with doses depending on age and phase.

A key administration condition is the requirement for the concomitant supply of elemental calcium (provided by the Calcium Carbonate in Calvimax) to ensure the clinical action of the synthetic vitamin D analog. The medicine may be taken with or without food.

Crucially, the dose of Calvimax is not fixed; it is highly individualized and adjusted based on required laboratory parameters. The entire therapeutic protocol necessitates close medical supervision and frequent monitoring of serum calcium levels, with the ultimate dose goal being to maintain concentrations within the designated therapeutic range of 9 mg/ dL to 10 mg/ dL.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Calvimax

The information presented here describes the types of research and general findings for the Calvimax combination (Calcium Carbonate and Dihydrotachysterol), drawing only from the official clinical evaluation evidence. This overview is not medical advice and does not include information about dosing, side effects, or instructions for use.


Evidence for Use in Hypoparathyroidism and Chronic Hypocalcemia

Research was conducted in populations with chronic hypoparathyroidism and chronic hypocalcemia. Research examined the use of this combination in Randomized Controlled Trials (RCTs), where it was often compared against newer treatment approaches, as well as in long-term observational studies. Studies monitored physiological strain by measuring blood markers like serum calcium and serum phosphorus levels. Research also described patterns in neuromuscular symptoms, which are considered outcomes related to physical discomfort. Data show patterns related to measured serum calcium levels, but evidence is limited regarding definitive long-term effects, such as patterns in fracture incidence over decades. Furthermore, long-term observational data was associated with findings related to renal events.


Evidence for Use in Renal Osteodystrophy and Related Mineral Disorders

This combination was studied for managing the bone and mineral disturbances (Mineral Bone Disorder) that occur in people with advanced Chronic Kidney Disease (CKD). Studies primarily monitored physiological strain, specifically focusing on shifts in Parathyroid Hormone (PTH) levels and tracking concentrations of serum calcium and serum phosphorus. The certainty remains low regarding long-term clinical endpoints such as fracture or mortality. Evidence for long-term clinical outcomes is often limited and mixed across the available studies, as most research focused on tracking biochemical markers.


Evidence for Use in Rickets and Osteomalacia

This combination was evaluated in research contexts involving these conditions marked by functional limitations and defective bone mineralization. Studies explored the use of a calcium source alongside an active vitamin D analog. Studies monitored outcomes related to systemic or functional imbalance, specifically tracking the normalization of serum mineral concentrations and using radiographic assessment to look at skeletal changes. Evidence suggests that modern comparative evidence is lacking for this specific combination against newer pharmacological options. Furthermore, there is limited information for long-term outcomes regarding the prevention of disease relapse, and studies noted the tracking of long-term renal function.


What Remains Uncertain in the Research Landscape

The evidence highlights what is known—and what is still uncertain—about the Calvimax combination. Research is ongoing, but several areas have key limitations. For many of the chronic uses, follow-up durations were limited in the controlled settings, meaning long-term effects are not fully established, particularly regarding fracture incidence and mortality. Comparative evidence is lacking for certain treatment scenarios. Research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted.

Key Studies & References Calcium (MedlinePlus Medical Encyclopedia)

Frequently Asked Questions (FAQ)

Common questions about Calvimax (FAQ)

Q: Is Calvimax considered a long-term or short-term treatment?

According to regulatory documents, Calvimax therapy is typically considered long-term. The treatment protocol involves a short initial phase with a higher dose, followed by a chronic, daily maintenance dose adjusted for the individual. The use of this medicine requires close medical supervision.

Q: How long does it usually take to feel the effects of Calvimax?

Official reports indicate the onset of action for the active Dihydrotachysterol component is typically observed within 4 to 7 days after starting treatment. Individual response times may vary, but this is the reported timeframe from official sources.

Q: Is Calvimax generally appropriate for older adults?

Official prescribing information advises caution when Calvimax is used by older adults. This is due to a potentially heightened risk of toxicity, especially the possibility of hypercalcemia (abnormally high calcium levels). The medicine’s use in this population requires close and frequent monitoring.

Q: Where can I find published clinical trial data for Calvimax?

Information about the clinical evaluation of Calvimax can be found by searching government clinical trial registries. These resources, such as ClinicalTrials.gov, serve as official sources for study information on the active ingredients.

Q: Is Calvimax known to cause changes in weight or appetite?

The official documentation lists loss of appetite (anorexia) as a common documented reaction. However, official information does not contain specific information regarding changes in body weight (gain or loss).

Q: Are there any known effects of Calvimax on sleep patterns?

The adverse reaction profile lists central nervous system effects such as lethargy and confusion. Specific effects on sleep quality are not explicitly detailed in official warnings.

Q: Is it normal to experience mild fatigue when starting Calvimax?

The drug's safety profile includes general symptoms such as weakness and lethargy, which are related to the feeling of fatigue. The presence of these symptoms may be reported to a healthcare provider as they could signal the need for evaluation.

Q: What happens in general if a person suddenly stops using Calvimax?

If Calvimax therapy is discontinued suddenly, the underlying mineral imbalance may return, potentially leading to symptoms of hypocalcemia (low calcium). Patients are monitored closely following any change in the therapeutic regimen.

Q: Does Calvimax interact with alcohol consumption?

Regulatory documents note a moderate interaction with alcohol, which is classified as a food/lifestyle interaction. The drug is associated with this interaction, and its consumption requires discussion with a healthcare provider.

Q: What makes Calvimax different from other treatments for the same condition?

Calvimax is described as a unique combination product. This dual composition, featuring both a mineral source (Calcium Carbonate) and a synthetic Vitamin D analog (Dihydrotachysterol), distinguishes it from single-entity medications.

Q: Why are people with a history of liver problems typically advised not to use Calvimax?

Official information states that caution is necessary for individuals with hepatic impairment (liver problems). The Dihydrotachysterol component is metabolized in the liver, and impairment may affect the predictability of its effects and increase toxicity risk.

Q: Does Calvimax need to be stored in a special way?

According to official product information, Calvimax must be stored at controlled room temperature, typically between 20 C and 25 C. The medicine must be kept in its original container, protected from light and moisture. It is important that the medicine is not frozen.

Q: Can Calvimax be taken by people with a history of heart conditions?

Regulatory documents state that caution is necessary for individuals with existing heart conditions. A potential risk of using Calvimax is hypercalcemia, which can potentiate cardiac arrhythmias (irregular heartbeats) and digitalis toxicity.

Q: Are there any specific dietary restrictions associated with Calvimax?

Official labeling documents specific dietary restrictions. High intake of Oxalic Acid or Phytic Acid may interfere with calcium absorption. Additionally, Grapefruit or Grapefruit Juice may alter the concentrations of Dihydrotachysterol.

Q: What are the common signs of an allergic reaction to Calvimax?

While the drug is contraindicated in patients with known hypersensitivity, typical signs of a serious allergic reaction that require immediate attention include skin rash, hives, or swelling.

Q: Does Calvimax affect a person's ability to drive or operate heavy machinery?

Because adverse reactions include confusion, lethargy, and syncope (fainting), patients are advised to exercise caution before engaging in activities like driving or operating heavy machinery.

Q: Is Calvimax used to prevent a condition or to treat an existing one?

Official indications state that Calvimax is approved for the treatment of conditions that result in chronic mineral imbalances, such as hypoparathyroidism and hypocalcemia. Its use is not approved for general prevention.

Q: What is the expected course of treatment with Calvimax?

The course of treatment is not defined by a fixed duration, but rather a sequence of two main phases. This involves a short period of initial loading doses followed by a long-term, chronic maintenance dose that is adjusted frequently based on laboratory testing.

Q: Can Calvimax cause changes in mood or anxiety levels?

Regulatory information indicates that nervous system adverse reactions, including confusion and lethargy, may occur. Specific information on changes in mood or anxiety levels is limited.

Q: What is the process for reporting side effects experienced with Calvimax?

Adverse effects may be reported by patients or healthcare providers to the official regulatory body responsible for drug safety monitoring. This is typically the national health authority.

Q: Are there any known long-term effects of Calvimax use mentioned in regulatory summaries?

Prolonged use is associated with risks of serious complications from prolonged hypercalcemia. These risks include Irreversible Renal Insufficiency and Metastatic Calcification of soft tissues, though official research data on long-term clinical endpoints remains limited.

Q: Does Calvimax affect the body's natural production of any substances?

Research studies monitor the drug’s influence on Parathyroid Hormone (PTH) levels, which is a substance naturally produced by the body to help control calcium.

Q: How does the use of Calvimax relate to fertility or pregnancy planning?

Official information states that the medication is classified as restricted for use during pregnancy. It is also generally not recommended during the lactation period due to a lack of established data.

Q: What research is currently ongoing regarding the uses or safety of Calvimax?

Ongoing research is indicated to address limitations in the existing evidence base, particularly regarding long-term effects in certain patient populations. This ensures the continuous monitoring of the drug's safety profile.

Q: What are the inactive ingredients in Calvimax?

The complete list of inactive ingredients, which may include components such as dextrose, corn starch, and magnesium stearate, is detailed in the official product labeling. These substances are used to create the medicine's form (e.g., tablet, suspension).

How should Calvimax be stored and disposed of?

Storing and Disposing of Calvimax

The storage and disposal of Calvimax (Calcium Carbonate and Dihydrotachysterol) must adhere strictly to official regulatory guidelines to preserve its stability.

Detail Regulatory Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C.
Protection Keep the product in a dry place and protect from light and moisture. Do not freeze the medicine.
Container Keep in the original container and ensure the container is tightly closed.

Child Safety: It is a mandatory requirement to keep Calvimax out of the sight and reach of children and pets at all times.

Disposal: The preferred method for discarding unused or expired product is a drug take-back program. If a take-back option is unavailable, the medicine must be removed from its container, mixed with an undesirable substance (like coffee grounds), placed in a sealed bag, and then thrown in the household trash. Do not flush the medication down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calvimax found in:

A-Z Index: